ORBIMED ADVISORS LLC 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:30 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,200,200 (Position Closed) |
Filing |
| 2022-02-11 4:27 pm Purchase |
2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
ORBIMED ADVISORS LLC | 2,200,200 4.300% |
2,200,200 (New Position) |
Filing |